Kun-Zhe Wu

426 total citations
19 papers, 319 citations indexed

About

Kun-Zhe Wu is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Kun-Zhe Wu has authored 19 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Cancer Research and 5 papers in Surgery. Recurrent topics in Kun-Zhe Wu's work include MicroRNA in disease regulation (5 papers), RNA modifications and cancer (5 papers) and Cancer-related molecular mechanisms research (5 papers). Kun-Zhe Wu is often cited by papers focused on MicroRNA in disease regulation (5 papers), RNA modifications and cancer (5 papers) and Cancer-related molecular mechanisms research (5 papers). Kun-Zhe Wu collaborates with scholars based in China and Japan. Kun-Zhe Wu's co-authors include Cheng Zhang, Dong‐Qiu Dai, Chun‐Dong Zhang, Ming-Hui Ma, Jun‐Peng Pei, Jinlan Jiang, Liang Yu, Beibei Yu, Yu Liang and Yangyang Tian and has published in prestigious journals such as Life Sciences, BioMed Research International and Genomics.

In The Last Decade

Kun-Zhe Wu

19 papers receiving 316 citations

Peers

Kun-Zhe Wu

ONCOL

PRM

SURGE

Yinghua Wu China

Yuanchao Zhu China

Yanrui Liang China

Lexiang Zeng China

Kyung‐Chae Jeong South Korea

Hailing Tang China

Wu-Ping Zheng China

Hamidreza Saebfar Iran

Chengzhi Huang China

Bo Liang China

Yinghua Wu China

Kun-Zhe Wu

160 ×1.0

117 ×1.0

56 ×0.8

ONCOL

136 ×2.0

PRM

45 ×1.0

SURGE

Citations per year, relative to Kun-Zhe Wu Kun-Zhe Wu (= 1×) peers Yinghua Wu

Countries citing papers authored by Kun-Zhe Wu

Since Specialization

Citations

This map shows the geographic impact of Kun-Zhe Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun-Zhe Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun-Zhe Wu more than expected).

Fields of papers citing papers by Kun-Zhe Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kun-Zhe Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun-Zhe Wu. The network helps show where Kun-Zhe Wu may publish in the future.

Co-authorship network of co-authors of Kun-Zhe Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Kun-Zhe Wu. A scholar is included among the top collaborators of Kun-Zhe Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kun-Zhe Wu. Kun-Zhe Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Li, Jianyang, et al.. (2023). Progress in the treatment of drug-loaded nanomaterials in renal cell carcinoma. Biomedicine & Pharmacotherapy. 167. 115444–115444. 10 indexed citations

Wu, Kun-Zhe, et al.. (2023). Co-delivery of curcumin and si-STAT3 with a bioinspired tumor homing for polydopamine nanoparticles for synergistic osteosarcoma therapy. Cancer Nanotechnology. 14(1). 6 indexed citations

Wu, Kun-Zhe, et al.. (2022). Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy. Diabetes Metabolic Syndrome and Obesity. Volume 15. 2653–2673. 10 indexed citations

Li, Jing, et al.. (2022). Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. International Journal of Nanomedicine. Volume 17. 5209–5227. 22 indexed citations

Wu, Kun-Zhe, et al.. (2022). Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: Current progress and future prospects. Biomedicine & Pharmacotherapy. 158. 114135–114135. 14 indexed citations

Wu, Kun-Zhe, Beibei Yu, Di Li, et al.. (2022). Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma. Frontiers in Oncology. 12. 805978–805978. 37 indexed citations

Yu, Beibei, et al.. (2022). Recent advances in nanoplatforms for the treatment of neuropathic pain. Spinal Cord. 60(7). 594–603. 6 indexed citations

Zhang, Cheng, Yu Liang, Chun‐Dong Zhang, et al.. (2021). The novel role and function of LINC01235 in metastasis of gastric cancer cells by inducing epithelial-mesenchymal transition. Genomics. 113(3). 1504–1513. 16 indexed citations

Pei, Jun‐Peng, Chun‐Dong Zhang, Liang Yu, et al.. (2020). A Modified Pathological N Stage Including Status of Tumor Deposits in Colorectal Cancer With Nodal Metastasis. Frontiers in Oncology. 10. 548692–548692. 22 indexed citations

10.

Pei, Jun‐Peng, Chun‐Dong Zhang, Liang Yu, et al.. (2020). Novel Nomograms Individually Predicting Overall Survival of Non-metastatic Colon Cancer Patients. Frontiers in Oncology. 10. 733–733. 12 indexed citations

11.

Zhang, Cheng, Chun‐Dong Zhang, Yu Liang, et al.. (2020). The comprehensive upstream transcription and downstream targeting regulation network of miRNAs reveal potential diagnostic roles in gastric cancer. Life Sciences. 253. 117741–117741. 8 indexed citations

12.

Pei, Jun‐Peng, Chun‐Dong Zhang, Cheng Zhang, et al.. (2020). Effects of epidural combined with general anesthesia versus general anesthesia alone in gastric cancer surgery: a propensity score matching analysis. Annals of Translational Medicine. 8(7). 473–473. 13 indexed citations

13.

Wu, Kun-Zhe, Chun‐Dong Zhang, Cheng Zhang, Jun‐Peng Pei, & Dong‐Qiu Dai. (2020). <p>miR-665 Suppresses the Epithelial–Mesenchymal Transition and Progression of Gastric Cancer by Targeting <em>CRIM1</em></p>. Cancer Management and Research. Volume 12. 3489–3501. 25 indexed citations

14.

Wu, Kun-Zhe, et al.. (2020). Identification of a nine-gene prognostic signature for gastric carcinoma using integrated bioinformatics analyses. World Journal of Gastrointestinal Oncology. 12(9). 975–991. 12 indexed citations

15.

Wu, Kun-Zhe, Chun‐Dong Zhang, Cheng Zhang, & Dong‐Qiu Dai. (2020). A Novel Three‐miRNA Signature Identified Using Bioinformatics Predicts Survival in Esophageal Carcinoma. BioMed Research International. 2020(1). 5973082–5973082. 7 indexed citations

16.

Zhang, Cheng, Ming-Hui Ma, Yu Liang, Kun-Zhe Wu, & Dong‐Qiu Dai. (2019). Novel long non-coding RNA LINC02532 promotes gastric cancer cell proliferation, migration, and invasion in vitro. World Journal of Gastrointestinal Oncology. 11(2). 91–101. 16 indexed citations

17.

Zhang, Cheng, Liang Yu, Ming-Hui Ma, Kun-Zhe Wu, & Dong‐Qiu Dai. (2019). KRT15, INHBA, MATN3, and AGT are aberrantly methylated and differentially expressed in gastric cancer and associated with prognosis. Pathology - Research and Practice. 215(5). 893–899. 39 indexed citations

18.

Zhang, Lirong, Xiaohua Xu, Tiechao Jiang, et al.. (2018). Citrus aurantium Naringenin Prevents Osteosarcoma Progression and Recurrence in the Patients Who Underwent Osteosarcoma Surgery by Improving Antioxidant Capability. Oxidative Medicine and Cellular Longevity. 2018(1). 8713263–8713263. 22 indexed citations

19.

Zhang, Cheng, Yu Liang, Ming-Hui Ma, et al.. (2018). Downregulation of microRNA-376a in Gastric Cancer and Association with Poor Prognosis. Cellular Physiology and Biochemistry. 51(5). 2010–2018. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact